Fintel reports that on April 1, 2025, HC Wainwright & Co. initiated coverage of Rezolve AI (NasdaqGM:RZLV) with a Buy ...

H.C. Wainwright raised the firm’s price target on BiomX (PHGE) to $21 from $2 and keeps a Buy rating on the shares. The new target reflects the ...

H.C. Wainwright lowered the firm’s price target on Adaptimmune (ADAP) to $3 from $3.50 and keeps a Buy rating on the shares following the Q4 ...

Stock analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Acumen Pharmaceuticals ...

HC Wainwright cut their FY2028 EPS estimates for shares of Gevo in a report released on Friday, March 28th. HC Wainwright ...

Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a ...

H.C. Wainwright & Co., LLC (“HCW”) announces a significant milestone, securing its #1 ranking for the 40th consecutive quarter in PlacementTracker’s Market League Tables by transaction volume. "This ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps ...

H.C. Wainwright keeps a Buy rating on Milestone Pharmaceuticals (MIST) after the company announced receipt of a complete response letter from the FDA regarding its new drug application for its ...

Fintel reports that on March 27, 2025, HC Wainwright & Co. initiated coverage of RenovoRx (NasdaqCM:RNXT) with a Buy recommendation. As of March 19, 2025, the average one-year price target for ...

In a report released today, Kevin Dede from H.C. Wainwright maintained a Hold rating on Biotricity (BTCY – Research Report). The company’s shares closed last Friday at $0.50.